Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
已完结10由 Aixuexi 发布于 2026/8/3 10:11:49
DOI:10.1016/s0140-6736(25)01954-3
作者:Yunpeng Yang, Huaqiang Zhou, Linquan Tang, Sufang Qiu, Yaqian Han, Dongmei Ji, Xiaozhong Chen, Feng Lei, Song Qu, Bin Deng, Lusi Chen, Jianli Huang, Ye Guo, Zhigang Liu, Dongping Chen, Jingao Li, Xiao
文献类型:期刊论文
补充材料:只需要正文